Sarepta Therapeutics, Inc. (SRPT) financial statements and ratios from SEC XBRL: revenue $2.20B (latest fiscal year), net margin -32.5%, revenue growth 15.6% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $2.20B |
| Net Margin | -32.5% |
| Operating Margin (TTM) | -1.9% |
| Net Debt / EBITDA | 86.4 |
| Revenue Growth (YoY) | 15.6% |
| EPS Growth (YoY) | -388.7% |
| FCF Growth (YoY) | -10.3% |
| EV / EBITDA | 15.5 |
| Price / Book | 1.32 |
| Price / Sales | 0.80 |
| FCF Yield | -83.9% |
| Altman Z-Score | -1.02 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
SRPT overview · SRPT earnings · SRPT KPIs · SRPT documents · SRPT ownership · SRPT peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.